UroToday - The Global Online Community of Urologists
ƒ PDT³~ P„ sÿùþ¬ï ªòñ ÆÓ;Æ;–ñ“gà Mè47Ï Ò³³}S”°Ž± YòJ2„&üÿ{µ'°u €ƒ ø–Zh*@÷½ûÀ—þ yd ` ¸ 7 ïÌ}÷½÷¿¾,íÈ¥iV.š®é.ÛšÇNÙÚ`NpÝR; aNi,pOÐÀ… €†íc˜Öݾ¯·æQ@D ¦&c£ÜWJ() ÙMßF è9m_—¶ ³W]sâ $û N´á žVþïÃÍUµm´²ŠÑ 8 I©* n±âŒDa ËÔf áÁ[ AU‘R P»SÞ΄ Éks |} Üj§‹Ù»£k“íÎ$Û ...
UroToday - The Global Online Community of Urologists
UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
Upcoming Events for Urologists and Oncologists - UroToday
The International Prostate Cancer Update (IPCU), founded in 1991, is a multi-day, CME-accredited conference focused on prostate cancer treatment updates, with international faculty providing attendees with a variety of viewpoints and how-to instruction.
UroToday
Published 15 September 2024 (UroToday.com) The 2024 ESMO annual meeting included a session on urothelial carcinoma, featuring a presentation by Dr. Alexandra Drakaki, discussing ctDNA clearance with neoadjuvant durvalumab + tremelimumab + enfortumab vedotin for cisplatin-ineligible muscle invasive bladder cancer from the safety run-in …
About UroToday
About UroToday-GU Oncology Today ® UroToday - GU Oncology Today brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.This site presents content on critical areas of research and clinical practice, providing researchers and clinicians the opportunity to evaluate …
GU Onc Daily - UroToday
2024年8月27日 · World Congress of Endourology and Uro-Technology (WCET) 2024: Leave No Stone Unmeasured - Predicting Outcomes, and Innovations in Ureteroscopy Sent on 21 August 2024 Receive via e-mail
UroToday Video Channels
UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
ESMO 2024 Quick Take Insights: A Focus on SPLASH - urotoday.com
2024年10月17日 · ESMO 2024, metastatic castration resistant prostate cancer (mCRPC), SPLASH trial,177Lu-PSMA-617, PSMAfore trial, 177Lu-PNT2002, enzalutamide, abiraterone, VISION trial, androgen receptor pathway inhibitor (ARPI).
EAU 2024 Annual Meeting - UroToday
EAU 2024 Bladder Cancer. EAU 2024: Membranous NECTIN-4 Expression in Metastasis Versus Matched Primary Tumor More Accurately Predicts Enfortumab Vedotin Response
Clinical Trials in Urology - UroToday
2024年12月2日 · Cabozantinib, an oral tyrosine kinase inhibitor against MET and vascular endothelial growth factor receptor 2 (VEGFR2), is an agent that has had success in multiple tumor types, such as renal cell, hepatocellular and medullary thyroid cancer. There have been multiple randomized phase 3 trial ...